Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITC-6146RO in Advanced or Metastatic Cancer
NCT07423117Phase 1Enrolling by invitation
- Sponsor
- IntoCell
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ITC-6146RO in metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC) and 1 more, sponsored by IntoCell. Primary endpoint: Incidence of Adverse Events up to 2 years. Started Mar 2026; status: enrolling by invitation.
02
Drugs
ITC-6146RO
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)non-small cell lung cancer (NSCLC)triple negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT07423117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423117.